PCM
CSBR icon

Prelude Capital Management’s Champions Oncology CSBR Stock Holding History

Prelude Capital Management’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,360
Closed -$19K – 1966
2019
Q3 		$19K Sell
3,360
-48
-1% -$311 ﹤0.01% 1400
2019
Q2 		$27K Sell
3,408
-4,994
-59% -$43.8K ﹤0.01% 1239
2019
Q1 		$82K Buy
8,402
+2,502
+42% +$24.9K ﹤0.01% 987
2018
Q4 		$46K Buy
+5,900
New +$67.8K ﹤0.01% 1131

Other funds holding CSBR

BPI
Battery Partners IX Boston, Massachusetts $22.4M AUM 27.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
CPA
Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Prelude Capital Management's CSBR Position: Q4 2019 in Review

Prelude Capital Management sold out of Champions Oncology (CSBR) in Q4 2019, closing a stake of 3,360 shares — an estimated $19K sold.

Prelude Capital Management first reported a position in CSBR in Q4 2018 and held it in 4 quarters. The position peaked at $82K in Q1 2019. 32 funds tracked by Wall St. Rank hold CSBR as of Q4 2019.

  • Prelude Capital Management reported no remaining Champions Oncology position as of Q4 2019 after selling out during the quarter.
  • Prelude Capital Management sold 3,360 Champions Oncology shares in Q4 2019, an estimated $19K.
  • Prelude Capital Management first reported a position in Champions Oncology in Q4 2018 and held it in 4 quarters.
  • Prelude Capital Management's Champions Oncology position peaked at $82K in Q1 2019.
  • 32 funds tracked by Wall St. Rank held Champions Oncology as of Q4 2019.

Based on Prelude Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.